Circulating essential metals and lung cancer: Risk assessment and potential molecular effects

Bai, Yansen; Wang, Gege; Fu, Wenshan; Lu, Yanjun; Wei, Wei; Chen, Weilin; Wu, Xiulong; Meng, Hua; Feng, Yue; Liu, Yuhang; Li, Guyanan; Wang, Suhan; Wang, Ke; Dai, Juanxiu; Li, Hang; Li, Mengying; Huang, Jiao; Li, Yangkai; Wei, Sheng; Yuan, Jing; Yao, Ping; Miao, Xiaoping; He, Meian; Zhang, Xiaomin; Yang, Handong; Wu, Tangchun; Guo, Huan

doi:10.1016/j.envint.2019.04.021

Cited by 49 publications

(28 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, advanced disease had significantly higher whole blood (but not serum) Cu levels (1.19 vs. 0.81 mg/l, p < 0.05) compared to patients with lower clinical stages [ 58 ]. The same trend was recognized in a nested case-control study (0.95 vs. 0.90 mg/l, p = 0.044) with 440 incident LC cases and 1,320 matched healthy controls from the Dongfeng-Tongji Cohort (China) [ 26 ].…”

Section: Coppersupporting

confidence: 60%

“…Similarly, when 440 incident LC cases and matched 1,320 healthy controls from the Dongfeng-Tongji Cohort (China) were compared, both, cancer and control cases, showed comparable Se levels in plasma (60 vs. 59 μg/l, p = 0.551) [ 26 ]. SELENOP is supposed to be a more suitable marker to reflect the Se status.…”

Section: Seleniummentioning

confidence: 99%

“…[ 50 ]), but prospective studies are inconsistent regarding a possible link between high Cu levels and an increased cancer risk. While such an association has been described for CRC [ 51 ], it has not been reported for HCC and LC [ 26 , 36 , 52 ].…”

Section: Coppermentioning

confidence: 99%

“…However, a recent cross-sectional study including 3,607 participants did not reveal any association between serum Zn levels and the incidence of (all kind of) cancer in multivariate logistic regression analysis (OR = 1.001, p = 0.980) [ 62 ]. Contrary, many other studies indicate an inverse relationship between Zn intake/levels and cancer risk of various tissue types, e.g., BC [ 48 ], LC [ 26 , 36 ], CRC [ 37 , 51 ], and HCC [ 52 ].…”

Section: Zincmentioning

confidence: 99%

“…Here, 27 from 32 studies (including 2,894 cases and 9,419 controls), mostly from Asia (including three European studies), indicated lower serum Zn levels in LC patients than in controls (SMD = −0.88, p < 0.001), while in four and two studies no significant and a positive association, respectively, were recognized. In a further nested case-control study 440 incident LC cases and 1,320 matched healthy controls were compared, revealing higher Zn levels in controls (1.18 vs. 1.28 mg/l, p = 0.019) [ 26 ].…”

Section: Zincmentioning

confidence: 99%

See 4 more Smart Citations

Are trace element concentrations suitable biomarkers for the diagnosis of cancer?

2021

View full text Add to dashboard Cite

Despite advances in cancer research, cancer is still one of the leading causes of death worldwide. An early diagnosis substantially increases the survival rate and treatment success. Thus, it is important to establish biomarkers which could reliably identify cancer patients. As cancer is associated with changes in the systemic trace element status and distribution, serum concentrations of selenium, iron, copper, and zinc could contribute to an early diagnosis. To test this hypothesis, case control studies measuring trace elements in cancer patients vs. matched controls were selected and discussed focusing on lung, prostate, breast, and colorectal cancer. Overall, cancer patients had elevated serum copper and diminished zinc levels, while selenium and iron did not show consistent changes for all four cancer types. Within the tumor tissue, mainly copper and selenium are accumulating. Whether these concentrations also predict the survival probability of cancer patients needs to be further investigated.

show abstract

Section: Coppersupporting

confidence: 60%

Section: Seleniummentioning

confidence: 99%

Section: Coppermentioning

confidence: 99%

Section: Zincmentioning

confidence: 99%

Section: Zincmentioning

confidence: 99%

See 3 more Smart Citations

Are trace element concentrations suitable biomarkers for the diagnosis of cancer?

2021

View full text Add to dashboard Cite

show abstract

Selenium and cancer risk: Wide‐angled Mendelian randomization analysis

Yuan

Mason

Carter

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

Evidence on the association between selenium and cancer risk is inconclusive. We conducted a Mendelian randomization study to examine the associations of selenium levels with 22 site‐specific cancers and any cancer. Single nucleotide polymorphisms (SNPs) strongly associated with toenail and blood (TAB) and blood selenium levels in mild linkage disequilibrium (r2 < .3) were used as instrumental variables. Genetic associations of selenium‐associated SNPs with cancer were obtained from the UK Biobank including a total of 59 647 cancer cases and 307 914 controls. Associations with P < .1 in UK Biobank were tested for replication in the FinnGen consortium comprising more than 180 000 individuals. The inverse‐variance weighted method accounting for linkage disequilibrium was used to estimate the associations. Genetically predicted TAB selenium levels were not associated with the risk of the 22 site‐specific cancers or any cancer (all 22 site‐specific cancers). Similarly, we observed no strong association for genetically predicted blood selenium levels. However, genetically predicted blood selenium levels showed suggestive associations with risk of kidney cancer (odds ratio [OR] per one‐unit increase in log‐transformed levels: 0.83; 95% confidence interval [CI]: 0.67‐1.03) and multiple myeloma (OR: 1.40; 95% CI: 1.02‐1.93). The same direction of association for kidney cancer but not for multiple myeloma was observed in FinnGen. In the metaanalysis of UK Biobank and FinnGen, the OR of kidney cancer was 0.83 (95% CI: 0.69‐1.00). Our study suggests that high selenium status may not prevent cancer development. The associations for kidney cancer and multiple myeloma need to be verified in well‐powered studies.

show abstract

Roles of zinc in cancers: From altered metabolism to therapeutic applications

Bendellaa,

Lelièvre,

Coll

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

Zinc (Zn) is a crucial trace element involved in various cellular processes, including oxidative stress, apoptosis and immune response, contributing to cellular homeostasis. Dysregulation of Zn homeostasis occurs in certain cancers. This review discusses the role of Zn in cancer and its associated components, such as Zn‐related proteins, their potential as biomarkers and the use of Zn‐based strategies for tumor treatment. ZIP and ZnT proteins regulate Zn metabolism under normal conditions, but their expression is aberrant in cancer. These Zn proteins can serve as prognostic or diagnostic biomarkers, aiding in early cancer detection and disease monitoring. Moreover, targeting Zn and its pathways offers potential therapeutic approaches for cancer treatment. Modulating Zn biodistribution within cells using metal‐binding agents allows for the control of downstream signaling pathways. Direct utilization of zinc as a therapeutic agent, including Zn supplementation or Zn oxide nanoparticle administration, holds promise for improving the prognosis of cancer patients.

show abstract

Circulating essential metals and lung cancer: Risk assessment and potential molecular effects

Cited by 49 publications

References 45 publications

Are trace element concentrations suitable biomarkers for the diagnosis of cancer?

Are trace element concentrations suitable biomarkers for the diagnosis of cancer?

Selenium and cancer risk: Wide‐angled Mendelian randomization analysis

Roles of zinc in cancers: From altered metabolism to therapeutic applications

Contact Info

Product

Resources

About